Relationship between obesity and gastroesophageal reflux disease and research progress on reflux treatment after bariatric surgery

doi:10.3877/cma.j.issn.2095-9605.2024.03.005

Abstract

Abstract:

The prevalence of both obesity and gastroesophageal reflux disease (GERD) is steadily increasing. Notably, the incidence of GERD in patients with obesity undergoing bariatric surgery is also on the rise. This could be attributed to factors such as esophageal sphincter dysfunction, elevated gastric pressure, and alterations in digestive tract anatomy following surgery. This paper aims to investigate the link between obesity and GERD, focusing on the underlying mechanisms and the challenges of treating GERD after bariatric surgery. The primary objective is to explore effective and safe treatment strategies for managing reflux in patients post-bariatric surgery.

Key words: Obesity, Gastroesophageal reflux disease, Bariatric surgery, Surgical treatment, Sleeve gastrectomy, Endoscopic therapy

Mingjie Guo, Chunqi Zhou, Jiahui Yu, Shihong Li, Hongmei Zhu, Yanjun Liu, Huawu Yang. Relationship between obesity and gastroesophageal reflux disease and research progress on reflux treatment after bariatric surgery[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(03): 184-192.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2024.03.005

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2024/V10/I03/184

Figures/Tables 4

References 66

[1]	成军, 窦攀, 段盛林, 等. 中国超重/肥胖医学营养治疗指南(2021) [J]. 中国医学前沿杂志(电子版), 2021, 13 (11): 1-55.
[2]	Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults [J]. The Lancet, 2024: S0140673623027502.
[3]	Dent J. Epidemiology of gastro-oesophageal reflux disease: a systematic review [J]. Gut, 2005, 54(5): 710-717.
[4]	Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus [J]. The American Journal of Gastroenterology, 2006, 101(8): 1900-1920.
[5]	El-Serag HB, Graham DY, Satia J A, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis [J]. The American Journal of Gastroenterology, 2005, 100(6): 1243-1250.
[6]	Stein DJ, El‐Serag HB, Kuczynski J, et al. The association of body mass index with Barrett’s oesophagus [J]. Alimentary Pharmacology & Therapeutics, 2005, 22(10): 1005-1010.
[7]	Nimptsch K, Steffen A, Pischon T. Obesity and Oesophageal Cancer [M]//Pischon T, Nimptsch K. Obesity and Cancer: Vol. 208. Cham: Springer International Publishing, 2016: 67-80.
[8]	Nam SY, Choi IJ, Ryu KH, et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women [J]. Gastroenterology, 2010, 139(6): 1902-1911.e2.
[9]	Stephens T W, Basinski M, Bristow P K, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product [J]. Nature, 1995, 377(6549): 530-532.
[10]	Landecho M F, Tuero C, Valentí V, et al. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk [J]. Nutrients, 2019, 11(11): 2664.
[11]	Park H K, Ahima R S. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism [J]. Metabolism, 2015, 64(1): 24-34.
[12]	Woods S C, Schwartz M W, Baskin D G, et al. Food intake and the regulation of body weight [J]. Annual Review of Psychology, 2000, 51(1): 255-277.
[13]	Banks W A, DiPalma C R, Farrell C L. Impaired transport of leptin across the blood-brain barrier in obesity [J]. Peptides, 1999, 20(11): 1341-1345.
[14]	Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications [J]. Nature Clinical Practice Endocrinology & Metabolism, 2006, 2(6): 318-327.
[15]	Abdelkader NA, Montasser IF, Bioumy EE, et al. Impact of anthropometric measures and serum leptin on severity of gastroesophageal reflux disease [J]. Diseases of the Esophagus, 2015, 28(7): 691-698.
[16]	Murata T, Asanuma K, Ara N, et al. Leptin aggravates reflux esophagitis by increasing tissue levels of macrophage migration inhibitory factor in rats [J]. The Tohoku Journal of Experimental Medicine, 2018, 245(1): 45-53.
[17]	Hotta K, Funahashi T, Bodkin N L, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J]. Diabetes, 2001, 50(5): 1126-1133.
[18]	Greer KB, Falk GW, Bednarchik B, et al. Associations of serum adiponectin and leptin with barrett’s esophagus [J]. Clinical Gastroenterology and Hepatology, 2015, 13(13): 2265-2272.
[19]	El-Serag HB, Tran T, Richardson P, et al. Anthropometric correlates of intragastric pressure [J]. Scandinavian Journal of Gastroenterology, 2006, 41(8): 887-891.
[20]	Del Grande LDM, Herbella FAM, Patti MG. The role of the transdiaphragmatic pressure gradient (TGP) in the Pathophysiology of Proximal Reflux [J]. Journal of Gastrointestinal Surgery, 2021, 25(2): 351-356.
[21]	Becker V. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors [J]. World Journal of Gastroenterology, 2014, 20(14): 4017.
[22]	Küper MA, Kramer KM, Kischniak A, et al. Dysfunction of the lower esophageal sphincter and dysmotility of the tubular esophagus in morbidly obese patients [J]. Obesity Surgery, 2009, 19(8): 1143-1149.
[23]	Wu JC, Mui L, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation [J]. Gastroenterology, 2007, 132(3): 883-889.
[24]	Franzén T. Is the severity of gastroesophageal reflux dependent on hiatus hernia size? [J]. World Journal of Gastroenterology, 2014, 20(6): 1582.
[25]	Sawada A, Rogers B, Visaggi P, et al. Effect of hiatus hernia on reflux patterns and mucosal integrity in patients with non-erosive reflux disease [J]. Neurogastroenterology & Motility, 2022, 34(11): e14412.
[26]	Iwakiri K, Tanaka Y, Hayashi Y, et al. Association between reflux esophagitis and/or hiatus hernia and gastric mucosal atrophy level in Japan [J]. Journal of Gastroenterology and Hepatology, 2007, 22(12): 2212-2216.
[27]	Yen HH, Tseng PH, Shih MC, et al. Derangement of esophageal anatomy and motility in morbidly obese patients: a prospective study based on high-resolution impedance manometry [J]. Surgery for Obesity and Related Diseases, 2020, 16(12): 2006-2015.
[28]	Kleidi E, Theodorou D, Albanopoulos K, et al. The effect of laparoscopic sleeve gastrectomy on the antireflux mechanism: can it be minimized? [J]. Surgical Endoscopy, 2013, 27(12): 4625-4630.
[29]	Namikawa T, Kitagawa H, Okabayashi T, et al. Roux-en-Y reconstruction is superior to billroth I reconstruction in reducing reflux esophagitis after distal gastrectomy: special relationship with the angle of his [J]. World Journal of Surgery, 2010, 34(5): 1022-1027.
[30]	Zhang C, Hu ZW, Yan C, et al. Nissen fundoplication vs proton pump inhibitors for laryngopharyngeal reflux based on pH-monitoring and symptom-scale [J]. World Journal of Gastroenterology, 2017, 23(19): 3546.
[31]	Arterburn DE, Telem DA, Kushner RF, et al. Benefits and Risks of Bariatric Surgery in Adults: A Review [J]. JAMA, 2020, 324(9): 879.
[32]	Ivezaj V, Barnes RD, Cooper Z, et al. Loss-of-control eating after bariatric/sleeve gastrectomy surgery: Similar to binge-eating disorder despite differences in quantities [J]. General Hospital Psychiatry, 2018, 54: 25-30.
[33]	Felsenreich DM, Bichler C, Langer FB, et al. Sleeve Gastrectomy: Surgical Technique, Outcomes, and Complications [J]. Surgical Technology International, 2020, 36: 63-69.
[34]	Yeung KTD, Penney N, Ashrafian L, et al. Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux? A Systematic Review and Meta-analysis [J]. Annals of Surgery, 2020, 271(2): 257-265.
[35]	Lim CH, Lee PC, Lim E, et al. Correlation Between Symptomatic Gastro-Esophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) Post-vertical Sleeve Gastrectomy (VSG) [J]. Obesity Surgery, 2019, 29(1): 207-214.
[36]	Popescu AL, Ioniţa-Radu F, Jinga M, et al. Laparoscopic sleeve gastrectomy and gastroesophageal reflux [J]. Romanian Journal of Internal Medicine, 2018, 56(4): 227-232.
[37]	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 腹腔镜Roux-en-Y胃旁路术规范化手术操作指南(2019版) [J/CD]. 中华肥胖与代谢病电子杂志, 2019, 5 (2): 63-69.
[38]	Chiappetta S, Stier C, Scheffel O, et al. Mini/One Anastomosis Gastric Bypass Versus Roux-en-Y Gastric Bypass as a Second Step Procedure After Sleeve Gastrectomy-a Retrospective Cohort Study [J]. Obesity Surgery, 2019, 29(3): 819-827.
[39]	Nadaleto BF, Herbella FAM, Patti MG. Gastroesophageal reflux disease in the obese: Pathophysiology and treatment [J]. Surgery, 2016, 159(2): 475-486.
[40]	Gorodner V, Matucci A, Solé L, et al. Does Roux-en-Y gastric bypass really cure gastroesophageal reflux disease? analysis of objective data [J]. J Laparoendosc Adv Surg Tech A, 2022, 32(2): 103-110.
[41]	Carbajo MA, Luque-de-León E, Jiménez JM, et al. Laparoscopic one-anastomosis gastric bypass: technique, results, and long-term follow-up in 1200 patients [J]. Obesity Surgery, 2017, 27(5): 1153-1167.
[42]	Chiappetta S, Weiner R. Evidence of the Mini-/One-anastomosis-gastric-Bypass for being a standard procedure in obesity and metabolic surgery [J]. Der Chirurg, 2018, 89(8): 589-596.
[43]	Esparham A, Ahmadyar S, Zandbaf T, et al. Does one-anastomosis gastric bypass expose patients to gastroesophageal reflux: a systematic review and meta-analysis [J]. Obesity Surgery, 2023, 33(12): 4080-4102.
[44]	Tjon JA, Pe M, Soscia J, et al. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease [J]. Pharmacotherapy, 2013, 33(9): 956-971.
[45]	f Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression [J]. BMC Medicine, 2016, 14(1): 179.
[46]	Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date [J]. Therapeutic Advances in Gastroenterology, 2018, 11: 1756283X1774577.
[47]	Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease [J]. World Journal of Gastroenterology, 2022, 28(28): 3608-3619.
[48]	Li S, Shi S, Chen F, et al. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials [J]. Gastroenterology Research and Practice, 2014, 2014: 1-8.
[49]	Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021 [J]. Journal of Gastroenterology, 2022, 57(4): 267-285.
[50]	Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations [J]. Therapies, 2021, 76(1): 13-21.
[51]	Franciosa M, Triadafilopoulos G, Mashimo H. Stretta Radiofrequency Treatment for GERD: A Safe and Effective Modality [J]. Gastroenterology Research and Practice, 2013, 2013: 1-8.
[52]	Fass R, Cahn F, Scotti DJ, et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease [J]. Surgical Endoscopy, 2017, 31(12): 4865-4882.
[53]	Rodríguez De Santiago E, Albéniz E, Estremera-Arevalo F, et al. Endoscopic anti-reflux therapy for gastroesophageal reflux disease [J]. World Journal of Gastroenterology, 2021, 27(39): 6601-6614.
[54]	Hu HQ, Li HK, Xiong Y, et al. Peroral endoscopic cardial constriction in gastroesophageal reflux disease [J]. Medicine, 2018, 97(15): e0169.
[55]	Sumi K, Inoue H, Kobayashi Y, et al. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: Experience of 109 cases [J]. Digestive Endoscopy, 2021, 33(3): 347-354.
[56]	Hedberg HM, Kuchta K, Ujiki MB. First Experience with Banded Anti-reflux Mucosectomy (ARMS) for GERD: Feasibility, Safety, and Technique (with Video) [J]. Journal of Gastrointestinal Surgery, 2019, 23(6): 1274-1278.
[57]	Garg R, Mohammed A, Singh A, et al. Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis [J]. Endoscopy International Open, 2022, 10(6): E854-E864.
[58]	Mason RJ, Hughes M, Lehman GA, et al. Endoscopic augmentation of the cardia with a biocompatible injectable polymer (Enteryx) in a porcine model [J]. Surgical Endoscopy And Other Interventional Techniques, 2002, 16(3): 386-391.
[59]	Frazzoni M. Laparoscopic fundoplication for gastroesophageal reflux disease [J]. World Journal of Gastroenterology, 2014, 20(39): 14272.
[60]	Humphries LA, Hernandez JM, Clark W, et al. Causes of dissatisfaction after laparoscopic fundoplication: the impact of new symptoms, recurrent symptoms, and the patient experience [J]. Surgical Endoscopy, 2013, 27(5): 1537-1545.
[61]	Lee Y, Tahir U, Tessier L, et al. Long-term outcomes following Dor, Toupet, and Nissen fundoplication: a network meta-analysis of randomized controlled trials [J]. Surgical Endoscopy, 2023, 37(7): 5052-5064.
[62]	Li S, Jiao S, Zhang S, et al. Revisional surgeries of laparoscopic sleeve gastrectomy [J].
[63]	Diabetes Metab Syndr Obes, 2021, 14: 575-588.
[64]	Ganam S, Tang R, Sher T, et al. Quality of life in patients undergoing revisional bariatric surgery: from sleeve gastrectomy to Roux-en-Y gastric bypass [J]. Obesity Surgery, 2024, 34(3): 997-1003.
[65]	Lee MH, Almalki OM, Lee WJ, et al. Outcomes of laparoscopic revisional conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: Different strategies for obese and non-obese Asian patients [J]. Asian Journal of Surgery, 2023, 46(2): 761-766.
[66]	Rayman S, Assaf D, Azran C, et al. Sleeve gastrectomy failure-revision to laparoscopic one-anastomosis gastric bypass or Roux-n-Y gastric bypass: a multicenter study [J]. Obesity Surgery, 2021, 31(7): 2927-2934.

Please choose a citation manager

Content to export